Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 20;14(10):2139. doi: 10.3390/nu14102139

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Serum NfL concentrations by treatment group, starter status, and risk. (A) Serum NfL concentrations (pg/mL) in the treatment and placebo groups at baseline, mid-season (week 17), and at end of treatment (week 26). (B) Serum NfL concentrations (pg/mL) in starters and non-starters at baseline, mid-season (week 17), and at end of treatment (week 26). (C) Serum NfL concentrations (pg/mL) in high- and low-risk position groups at baseline, mid-season (week 17), and at end of treatment (week 26). NfL, neurofilament light; p-values show significance within groups from baseline values (+) according to repeated measures ANOVA and estimated marginal means; p-values + p < 0.05; ++ p < 0.01, +++ p < 0.001.